LEUKEMIA IS A TYPE OF CANCER THAT AFFECTS THE BLOOD OR BONE MARROW. 1 ONE TYPE IS PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID (MY’-uh-loyd) LEUKEMIA.

SOME PATIENTS WITH C-M-L MAY HAVE DIFFICULTY FINDING A TREATMENT THAT’S RIGHT FOR THEM.

ALMOST 15% OF C-M-L PATIENTS DISCONTINUE THEIR TREATMENT IN THE FIRST YEAR DUE TO SIDE EFFECTS, SO HAVING DIFFERENT OPTIONS IS CRITICAL.3-7

HERE TO SHARE HER OWN EXPERIENCE BEING DIAGNOSED WITH PHILADELPHIA CHROMOSOME-POSITIVE C-M-L IN CHRONIC PHASE AND HOW SHE FOUND A TREATMENT THAT WORKED FOR HER, IS TEACHER AND C-M-L PATIENT, JEN. AND HERE TO TALK ABOUT TREATING ADULTS WITH C-M-L, IS DR. JAMES DUGAN (DOO’-guhn.)

HCP Bio: Dr. James Dugan

Dr. James Dugan is a hematology/oncology specialist, and the physician lead for the transplant and cellular therapy department for Novant Health Cancer Institute in Winston-Salem, North Carolina.

Dr. Dugan was drawn to the field of oncology by the opportunity to improve a person’s life during a difficult time. He believes that to properly treat the whole person and not just the disease, physicians need to engage in active conversations with the patient throughout the treatment process. Dr. Dugan approaches medicine and oncology as a partnership between the physician and the patient.

Dr. Dugan is a member of the American Society of Hematology, as well as the American Society for Transplant and Cellular therapy. His membership in these organizations keeps him up-to-date on the latest research and treatment options in the field.

When he is not seeing patients, Dr. Dugan enjoys time with his wife and three daughters. He is an outdoor enthusiast who enjoys skiing, scuba diving, kite surfing, and long-distance running. He is passionate about the shared human experience and loves meeting new people and exploring new ideas and places.

Patient Bio: Jen

In 2014, Jen was diagnosed with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
Prior to her diagnosis, Jen devoted her career to serving others. After dedicating 20 years to running inner-city youth programs, Jen became a social worker, supporting women as they rebuilt their lives after incarceration or experiencing domestic violence.
Jen was actively working as a social worker when she was diagnosed with CML. Unfortunately, her diagnosis required her to step away from her career for a period of time. Working closely with her doctor, she navigated the treatment landscape to find a treatment option that worked for her.
Today, she is a teacher in her rural community, educating K-8 students in a one-room schoolhouse. She is also passionate about sharing her journey and advocating for other adults with CML, helping them access the information and support they need to have meaningful conversations with their doctors and navigate their own patient journeys.

LearnCML.com

The post LEUKEMIA IS A TYPE OF CANCER THAT AFFECTS THE BLOOD OR BONE MARROW. appeared first on Good News!.

NIH study advances personalized immunotherapy for metastatic breast cancer

An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute’s (NCI) Center for Cancer Research, part of the National Institutes of Health. Many people with metastatic breast cancer can mount an immune reaction against their tumors, the study found, a prerequisite for this type of immunotherapy, which relies on what are called tumor-infiltrating lymphocytes (TILs).

In a clinical trial of 42 women with metastatic breast cancer, 28 (or 67%) generated an immune reaction against their cancer. The approach was used to treat six women, half of whom experienced measurable tumor shrinkage. Results from the trial appeared Feb. 1, 2022, in the Journal of Clinical Oncology.

“It’s popular dogma that hormone receptor–positive breast cancers are not capable of provoking an immune response and are not susceptible to immunotherapy,” said study leader Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch in NCI’s Center for Cancer Research. “The findings suggest that this form of immunotherapy can be used to treat some people with metastatic breast cancer who have exhausted all other treatment options.”

Immunotherapy is a treatment that helps a person’s own immune system fight cancer. However, most available immunotherapies, such as immune checkpoint inhibitors, have shown limited effectiveness against hormone receptor–positive breast cancers, which are the majority of breast cancers.

The immunotherapy approach used in the trial was pioneered in the late 1980s by Dr. Rosenberg and his colleagues at NCI. It relies on TILs, T cells that are found in and around the tumor.

TILs can target tumor cells that have specific proteins on their surface, called neoantigens, that the immune cells recognize. Neoantigens are produced when mutations occur in tumor DNA. Other forms of immunotherapy have been found to be effective in treating cancers, such as melanoma, that have many mutations, and therefore many neoantigens. Its effectiveness in cancers that have fewer neoantigens, such as breast cancer, however, has been less clear.

The results of the new study come from an ongoing phase 2 clinical trial being carried out by Dr. Rosenberg and his colleagues. This trial was designed to see if the immunotherapy approach could lead to tumor regressions in people with metastatic epithelial cancers, including breast cancer. In 2018, the researchers showed that one woman with metastatic breast cancer who was treated in this trial had complete tumor shrinkage, known as a complete response.

In the trial, the researchers used whole-genome sequencing to identify mutations in tumor samples from 42 women with metastatic breast cancer whose cancers had progressed despite all other treatments. The researchers then isolated TILs from the tumor samples and, in lab tests, tested their reactivity against neoantigens produced by the different mutations in the tumor.

Twenty-eight women had TILs that recognized at least one neoantigen. Nearly all the neoantigens identified were unique to each patient.

“It’s fascinating that the Achilles’ heel of these cancers can potentially be the very gene mutations that caused the cancer,” said Dr. Rosenberg. “Since that 2018 study, we now have information on 42 patients, showing that the majority give rise to immune reactions.”

For the six women treated, the researchers took the reactive TILs and grew them to large numbers in the lab. They then returned the immune cells to each patient via intravenous infusion. All the patients were also given four doses of the immune checkpoint inhibitor pembrolizumab (Keytruda) before the infusion to prevent the newly introduced T cells from becoming inactivated.

After the treatment, tumors shrank in three of the six women. One is the original woman reported in the 2018 study, who remains cancer free to this day. The other two women had tumor shrinkage of 52% and 69% after six months and 10 months, respectively. However, some disease returned and was surgically removed. Those women now have no evidence of cancer approximately five years and 3.5 years, respectively, after their TIL treatment.

The researchers acknowledged that the use of pembrolizumab, which has been approved for some early-stage breast cancers, may raise uncertainties about its influence on the outcome of TIL therapy. However, they said, treatment with such checkpoint inhibitors alone has not led to sustained tumor shrinkage in people with hormone receptor–positive metastatic breast cancer.

Dr. Rosenberg said that with the anticipated opening early this year of NCI’s new building devoted to cell-based therapies, he and his colleagues can begin treating more individuals with metastatic breast cancer as part of the ongoing clinical trial. He noted that this new immunotherapy approach could potentially be used for people with other types of cancer as well.

“We’re using a patient’s own lymphocytes as a drug to treat the cancer by targeting the unique mutations in that cancer,” he said. “This is a highly personalized treatment.”

About the Center for Cancer Research (CCR): CCR comprises nearly 250 teams conducting basic, translational, and clinical research in the NCI intramural program — an environment supporting innovative science aimed at improving human health. CCR’s clinical program is housed at the NIH Clinical Center — the world’s largest hospital dedicated to clinical research. For more information about CCR and its programs, visit ccr.cancer.gov.

About the National Cancer Institute (NCI): NCI leads the National Cancer Program and NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at cancer.gov or call NCI’s contact center, the Cancer Information Service, at 1-800-4-CANCER (1-800-422-6237).

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit nih.gov

#cancer #rosenberg #national #institute #health #research #breast #immunotherapy #patients #metastatic #tumor #fight #lymphocytes #oncology #infiltrating #immune #response #cells #dna #science

The post National Cancer Institute Researcher — Exciting Finding in Fight Against Breast Cancer (And Potentially Others) appeared first on Good News!.

Approximately 1 in 5 people living with cancer in the United States are diagnosed with a rare cancer; however, these are often misunderstood and overlooked. Cholangiocarcinoma, or CCA, is a rare cancer affecting fewer than 10,000 people in the U.S. CCA arises from the cells within the bile ducts, a series of thin tubes that reach from the liver to the small intestine. Because of its nonspecific symptoms, patients with CCA are often diagnosed at a late or advanced stage when the prognosis is poor and survival rates are low.

www.testmycholangio.com

Innovative technology called biomarker testing has made it possible to look very closely inside each person’s tumors to identify genomic changes. Determining the genomic makeup of a person’s tumor can help doctors understand more about the tumor.

National Cancer Survivors Day serves as an opportunity to rally around those living with CCA and other rare cancers, recognizing the challenges they face, and providing the community with the national attention they need and deserve. Dr. Rachna Shroff discusses CCA, along with importance of biomarker testing. Dr. Shroff is joined by Melinda Bachini, Director of Advocacy for the Cholangiocarcinoma Foundation and a CCA survivor, who will share her personal symptom and diagnosis journey.

Interview is courtesy of Incyte Corporation

Rachna T. Shroff, MD, MS, is an Associate Professor of Medicine and Chief of GI Medical Oncology as well as Leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center (UACC). She is the Director of UACC’s Clinical Trials Office as well as the Director of the Arizona Clinical Trials Network (ACTN). More recently, she was appointed as the Associate Dean for Clinical and Translational Research for UA College of Medicine-Tucson. She came to UACC from MD Anderson Cancer Center in Houston, TX where she was on faculty from 2010-2018 after completing her medical oncology fellowship there.

Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and biliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary subcommittee Co-Chair for the Southwest Oncology Group (SWOG) and as a Program Committee member for GI ASCO. She also is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the national PI for SWOG 1815 which is investigating a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase 2 study she led that is now published in JAMA Oncology. Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and has numerous peer-reviewed publications in this area.

BIO
Melinda Bachini is an 11-year survivor of cholangiocarcinoma. In 2012 she was treated at the National Cancer Institute by Dr. Rosenberg with a clinical trial using Adoptive Cell Therapy with TIL. Due to her exceptional and breakthrough response to NIH treatment, her story was published in the New York Times and other media.

Melinda is married and the mother of six children, grandmother to one. She is passionate about patient advocacy. Her personal experience with previous and current treatments allows for great insight into patients participating in clinical trials. Her position as Director of Advocacy for the Cholangiocarcinoma Foundation allows Melinda to interact, support and educates others touched by this cancer. She shares her story with as many cancer patients as possible in hopes of giving courage to those in need.

Melinda had previously volunteered for seven years with the Cholangiocarcinoma Foundation and in August of 2017 came on as staff. She also worked for over 15 years in the Emergency Medical Field as an EMT Paramedic.

Melinda serves as a patient advocate for the NCI Hepatobiliary Task Force, the NCI Patient Advocate Steering Committee (PASC), ECOG-ACRIN GI Committee, ECOG-ACRIN Cancer Research Advocacy Committee, NCI Council of Research Advocates, and the NCCN Hepatobiliary Guideline Panel. Melinda attended 2016, 2017, and 2018 NCCS, CPAT Symposium, and advocated on Capitol Hill. She participated as a panelist in the Cancer Moonshot – Community Oncology Event at the White House, told her personal story, and was introduced by her state Senator for the Innovation and Access in Quality Cancer Care at the US Capitol. In June of 2017 she spoke with nine US Senators at NIH to share her personal story of how research has prolonged her life. Melinda has served as a Consumer Reviewer for the Department of Defense for several years.

#cancer #survivor #cholangiocarcinoma #navigating #diagnosis #rachna #shroff #melinda #bachini #incyte #cca #medical #educate #support #emergency #liver #pancreatic #biliary #hepatobiliary #oncology

The post National Cancer Survivors Day is June 6, We discuss Cholangiocarcinoma appeared first on Good News!.

Important advancement in treatment for patients living with Follicular Lymphoma (FL)

• Dr. M. Yair Levy, Texas Oncology – Baylor Charles A. Sammons Cancer Center

BACKGROUND:
Cancer is a disease that almost everyone will confront at some point in their lives, either personally or through a loved one. As we continue to be impacted by the COVID-19 pandemic, it’s more important than ever to ensure patients receive proper care when managing a chronic cancer, like follicular lymphoma (FL).1

FL is a slow-growing and incurable blood cancer that starts in the lymphatic system, which is a system of lymph nodes found throughout the body, including the neck, underarms, chest, abdomen and groin/pelvis.1 While FL can occur at any age, it is most frequently diagnosed among people aged 55-64, with a median age of 63.2 Of the estimated 74,000 individuals diagnosed with non-Hodgkin lymphoma in the United States each year,3 FL accounts for approximately 20% of all cases, or about 14,800 individuals.1

It’s important for patients and doctors to remember that cancer care should not be put by the wayside due to COVID-19. By having routine and open conversations with healthcare providers via telemedicine and select in-person visits, patients can help to support their own improved health outcomes. There is also new hope as treatment advances give patients with FL, and the doctors who treat them, new, convenient options to help fight this debilitating cancer.

With the FDA’s recent accelerated approval of TAZVERIK® (tazemetostat) for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least 2 prior systemic therapies, FL patients have a new oral treatment option to discuss with their physicians. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). For more information on TAZVERIK, including full Prescribing Information, please visit: www.tazverik.com.4

Dr. M. Yair Levy, Texas Oncology – Baylor Charles A. Sammons Cancer Center, will be available for interviews. He will share details about this recent approval, risk factors, symptoms and treatment options for FL.
Interview is courtesy: Epizyme, Inc.

For more information on FL, please visit: www.lymphomaresearchfoundation.org or www.lls.org
For more information on TAZVERIK, including full Prescribing Information, please visit: www.tazverik.com

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

• Secondary Malignancies

The risk of developing secondary malignancies is increased following treatment with TAZVERIK. Across clinical trials of 729 adults who received TAZVERIK 800 mg twice daily, myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) occurred in 0.7% of patients. One pediatric patient developed T-cell lymphoblastic lymphoma (T-LBL). Monitor patients long-term for the development of secondary malignancies.

• Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug-associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure (area under the plasma concentration time curve [AUC0-45h]) at the 800 mg twice daily dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAZVERIK and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose.

Adverse Reactions

In 99 clinical study patients with relapsed or refractory follicular lymphoma receiving TAZVERIK 800 mg twice daily: Serious adverse reactions occurred in 30% of patients who received TAZVERIK. Serious adverse reactions occurring in ≥2% were general physical health deterioration, abdominal pain, pneumonia, sepsis, and anemia. The most common (≥20%) adverse reactions were fatigue (36%), upper respiratory tract infection (30%), musculoskeletal pain (22%), nausea (24%), and abdominal pain (20%).

Drug Interactions

Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. If coadministration of moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose.

Avoid coadministration of moderate and strong CYP3A inducers with TAZVERIK, which may decrease the efficacy of TAZVERIK.

Coadministration of TAZVERIK with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates.

Lactation

Because of the potential risk for serious adverse reactions from TAZVERIK in the breastfed child, advise women not to breastfeed during treatment with TAZVERIK and for one week after the final dose.

Please see full Prescribing Information for TAZVERIK, available at www.tazverik.com

MORE ABOUT DOCTOR*
Dr. Levy received his medical doctorate at the University of Wisconsin at Madison School of Medicine. He served his residency at the University of Pittsburgh Medical Center and his hematology fellowship at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD. He also served on the faculty at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Levy specializes in hematology, including lymphoma, myeloma and leukemia.

###

References:
1. Lymphoma- Non-Hodgkin: Introduction. Cancer.Net. Accessed September 15, 2020. Available at: https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/introduction
2. National Cancer Institute (NCI). Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: NHL – follicular lymphoma. Accessed September 15, 2020. Available at: https://seer.cancer.gov/statfacts/html/follicular.html.
3. About Non-Hodgkin Lymphoma. American Cancer Society. Accessed September 15, 2020. Available at: https://www.cancer.org/cancer/non-hodgkin-lymphoma/about.html.
4. TAZVERIK® (tazemetostat) Prescribing Information. Cambridge, Massachusetts, USA: Epizyme, Inc; June 2020.

*Spokespeople are subject to change based on availability. Individual experience with diagnosis and treatment of follicular lymphoma will vary by patient.

Produced for: Epizyme, Inc.

#yair #levy #hope #patients #living #incurable #blood #cancer #follicular #lymphoma #texas #oncology #disease #love #covid #covid-19 #covid19 #pandemic #lymph #nodes #tazverik #risk #factors #epizyme #hodgkin #lymphoma #foundation #safety

The post NEW HOPE FOR PATIENTS LIVING WITH AN INCURABLE BLOOD CANCER appeared first on Good News!.

NEW RESEARCH FROM PROMINENT CANCER MEETING FOR THOSE WITH LUNG CANCER

People with Lung Cancer, Like Others with Serious Underlying Medical Conditions
Might Be at an Increased Risk for Severe Illness from COVID-19

Lung cancer is the second most common cancer in both men and women. This year, an estimated 228,820 adults (116,300 men and 112,520 women) in the United States will be diagnosed.

The fight against lung cancer continues with new research and scientific advances, including cancer experts investigating potential ways to treat the disease in earlier stages. Some of these latest findings in non-small cell lung cancer (NSCLC), including investigational studies in earlier stages of the disease, were presented at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program.

Roy S. Herbst, MD, PhD of Yale Cancer Center and Smilow Cancer Hospital talks on the latest news from ASCO in the fight against lung cancer.

Lung cancer makes up almost 25% of all cancer deaths. There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the most common type of lung cancer. In fact, about 80%-85% of lung cancer cases are NSCLC. About 40% of patients are diagnosed at a later stage of disease, such as Stage IV, when the cancer has progressed to other organs. Approximately 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia have EGFRm NSCLC. The prevalence of EGFR mutations in early stage are estimated to be ~33% in a global NSCLC population.

Interview courtesy: AstraZeneca
#roy #harbst #yale #cancer #center #smilow #covid-19 #covid #19 #covid19 #lung #severe #illness #medical #risk #diagnosed #research #scientific #advances #disease #cell #nsclc #american #society #clinical #oncology #asco #virtual #hospital #astrazeneca

The post NEW RESEARCH FOR LUNG CANCER appeared first on Good News!.

BioTime is a biotechnology company focused on the emerging field of regenerative medicine. Our core technologies center on novel stem cells capable of becoming all of the cell types in the human body. Products made from these “pluripotent” stem cells are being developed by our subsidiaries, each of which concentrates on different medical specialties, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. BioTime’s commercial strategy targets near-term commercial opportunities such as Hextend and our current line of research products: ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, and GMP human embryonic stem cell lines. In addition, the launch of HyStem-Rx as a cell delivery device is expected in 2013, and the launch of PanC-Dx as a novel blood-based cancer screen is expected by 2014.  www.biotimeinc.com

Master Qi

The world renowned qi gong Great Master Qi Fei-Long is a Doctor ofTraditional Chinese Medicine(TCM), an honorable member of the China Medical Qi Gong Council, Advisor for International Science & Peace, President of the Flying Dragon Health 6c Nutrition Schooland the Chairman of ‘World Chinese Changes, Feng Shui and Astrology(Metaphysics) Academy.

From the age of seven years, Great Master Qi has had a very strong influence from his family TCM practice. Great Master Qi was precocious and showed extraordinary diligence and a superior talent in the Martial Arts. His profound understanding of Buddhism during his early childhood made him stand out among all others during his eight years of study and practice of Buddhism at the Shaolin Temple. For his remarkable achievements he was honored to receive special training from Great Master Su Yun the head of the Shaolin Temple. He learned the unique qi gong technique called “Chan Yuan Gong”.

Thereafter he became Master of the 31st Generation of the Jin Gang One Finger Stand of the Shaolin Temple (an extraordinary physical and mental feat performed by very few). After leaving Shaolin Temple, he had the privilege to learn “Tibetan Qi Gong” from both the Panchan Lama (second to the Dalai lama) and Xia Ridong, which is only passed on to a very few outstanding monks at the Tibetan Temple.

Great Master Qi Fei-long combined the “Chan Yuan Gong”and the “Tibean Qi Gong” to create his powerful “ChanMi Gong” which has been officially recognized by the Chinese Government as one of the most powerful and useful methods for gaining and retaining one’s good health. He also absorbed *re essences from the five major schools(Buddhism, Thoism, Confucianism, Traditional Chinese Medicine and Martial Art$ and created Shaolin ChanMi Gong. It is a meditative exercise with certain dynamic movements including gestures, codes and visualizations.

Shaolin ChanMi Gong is both easy to learn and extremely effective in building up well-being and in strengthening the immune system. It also acts as a “supplement” for self healing longevity and for developing a higher level of intelligence.

Great Master Qi Fei-long has developed some very special abilities using both universal and human energy. He uses his “qi” to educate people in the art of self-healing. Wiith his qi emission, he can set an ordinary newspaper on fire, slice through a number of plastic chopsticks with a $20 dallier bill, pull a solid building brick apart with his bare hands and stop the second hand of a wall clock, etc. His audiences and clients have always been duly impressed by the sight of these special abilities, which have been reported by major newspapers and tV stations in over 20 countries worldwide.

Great Master qi Fei-Long is also a world renowned Martial Arts Champion with scores of national and international honors and awards. He is both a judge and a referee of IKFF and a 9th Degree Black let from the International Kung-Fu Federation.

Great Master qi Fei-Long has developed a series of award winning health care products using special blends of herbs. Among them are the meditation cushion, cap and pillow all of which have gained patent status. These products not only enhance one’s qi effect, but also are useful in balancing Yin and Yan, opening meridians and assisting in the overall well-being of an individual.

www.shaolinworld.com

The post Michael West CEO of Bio Time and Qi-Fei-Long Master Eastern medicine Doctor appeared first on Good News!.